|
1. Biologie
|
|
|
|
3.1 Tabac
|
|
|
|
Jury still out on e-cigarettes as cessation aid, U.S. doctors say [Reuters]
|
|
|
|
|
|
The
conclusion, issued by the U.S. Preventive Services Task Force (USPSTF)
today as a part of updated recommendations on smoking cessation, adds to
an emerging consensus in the medical community that e-cigarettes come
with too many unknowns for them to be recommended to current smokers
looking to kick the habit.
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5. Traitements
|
|
|
Combination therapy could fight pancreatic cancer, say Stanford researchers [Scope Blog]
|
|
|
|
|
|
Although
much more research needs to be done, the investigators are hopeful
that, since vorinostat has already been approved by the Food and Drug
Administration, it could be possible to move more quickly than normal to
test this drug combination in patients with pancreatic cancer. They
also found intriguing hints that the duo may be effective in other types
of Ras-driven cancers, including lung adenocarcinoma.
|
|
|
|
|
|
|
Targeting DNA [MIT News]
|
|
|
|
|
|
MIT
biological engineers have developed a modular system of proteins that
can detect a particular DNA sequence in a cell and then trigger a
specific response, such as cell death.
|
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
With $75M, Deciphera Fuels Push For Cancer Drugs---And a Future IPO [Xconomy]
|
|
|
|
|
|
Taylor
contends this approach is distinctive in that it should lead to more
durable, longer-lasting kinase-inhibiting drugs, and be applicable to a
broader range of cancers. Deciphera’s drugs are designed to lock a
mutated kinase in its inactive shape so it can’t begin firing bad
signals—say, for a cell to grow uncontrollably.
|
|
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
What to Do About Turing (And the Others) [In the Pipeline]
|
|
|
|
|
|
Martin
Shkreli is going around saying that Turing is just a tiny little
company, raising prices on a tiny little drug – and although that’s
probably true, it doesn’t matter. This sort of thing could be a catalyst
for far bigger changes, and many of those would be very unpleasant for
the rest of the industry.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
‘Breakthrough’ drug may not mean what you think [Reuters]
|
|
|
|
|
|
“To
protect patients from spurious hopes for miracle cures, Congress and
the FDA should abandon the adoption of terminology like breakthrough and
focus on strengthening the evidentiary requirements for meaningful
clinical data to ensure the promise of new drugs and devices.”
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.8 Communication
|
|
|